CN103948689A - Medicinal composition for treating non-small cell lung cancer and application thereof - Google Patents
Medicinal composition for treating non-small cell lung cancer and application thereof Download PDFInfo
- Publication number
- CN103948689A CN103948689A CN201410151272.1A CN201410151272A CN103948689A CN 103948689 A CN103948689 A CN 103948689A CN 201410151272 A CN201410151272 A CN 201410151272A CN 103948689 A CN103948689 A CN 103948689A
- Authority
- CN
- China
- Prior art keywords
- chemotherapeutics
- lung cancer
- cell
- medicament
- cell lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition for treating non-small cell lung cancer. The medicinal composition comprises a target medicament, a chemotherapeutic medicament and a traditional Chinese medicament, wherein the target medicament is one or more of bortezomib, imatinib, gefitinib and sunitinib; the chemotherapeutic medicament is one or more of 5-fluorouracil, carboplatin, epirubicin, adriamycin and fludarabine; and the traditional Chinese medicament is one or more of salvia miltiorrhiza, astragalus membranaceus, sappanwood, Chinese pulsatilla root and portulaca oleracea. The medicinal composition has a remarkable synergetic treatment effect when being used for treating the non-small cell lung cancer, and can be used for remarkably strengthening the cancer-inhibition effect compared with treatment of a single medicament, so that the medicament dosage can be reduced, and the toxic and side effects of chemotherapeutic medicaments can be reduced.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to be used for the treatment of pharmaceutical composition and the application aspect treatment nonsmall-cell lung cancer thereof of nonsmall-cell lung cancer.
Background technology
Pulmonary carcinoma is the out of hand and a kind of disease that causes of lung tissue inner cell growth.Over nearly 50 years, the M & M increase year after year of pulmonary carcinoma, develops into the No.1 cancer killer in the current whole world from a kind of orphan disease in 20th century.According to statistics, in the many cities of industrialized country and China, the sickness rate of pulmonary carcinoma ranks first of male's kinds of tumor and women's common cancer second, and becomes the modal cause of death in malignant tumor.Expect 2025, the number of dying from pulmonary carcinoma is often only by China will approach 1,000,000, become the first in the world pulmonary carcinoma big country.
According to the differentiation degree of lung carcinoma cell and morphological characteristic, mainly pulmonary carcinoma is divided into clinically to small cell lung cancer (small cell lung cancer, SCLC) and nonsmall-cell lung cancer (non-small cell lung cancer, NSCLC) two large classes, wherein nonsmall-cell lung cancer accounts for 85% left and right.More than the summation of NSCLC causes in the world death toll carcinoma of prostate, breast carcinoma and colon cancer.Because NSCLC patient is in early days without obvious characteristic, although diagnostic method and treatment means make great progress, when 70% NSCLC cancer patient makes a definite diagnosis for the first time, still in cancer of late stage, wherein approximately 40% patient loses the chance of operative treatment.Therefore, chemotherapy and targeted therapy are most important for advanced NSCLC cancer patient.
Yet because chemotherapy is not had a selectivity, be difficult to form effective drug level or therapeutic dose at tumor by local, existing embolic chemotherapy only has certain effect to patient NSCLC less than 50%, and nearly all patient can be changed drug resistance pulmonary carcinoma in chemotherapy process, causes treatment to be lost efficacy.Simple raising chemotherapeutics concentration is subject to again the restriction of general toxic reaction.
In order to overcome the defect of chemotherapeutics, people start development with cell receptor, the molecular targeted therapy that key gene and regulatory molecule are target spot.Be applied at present the existing kind more than ten of molecular targeted agents of clinical treatment.For example, the kinase whose imatinib of Abl that targeting plays an important role in the development of chronic myelogenous leukemia, and targeting is in imatinib and the Sutent of the relevant tyrosine kinase of EGF-R ELISA, and by targeting proteasome enzyme inhibition, stop the bortezomib of cell death related protein matter metabolism.With respect to traditional chemotherapy means, it is strong that targeted drug treatment has selectivity, the feature that side effect is little, and it is more and more extensive that the application in oncotherapy has become.Yet the clinical practice of targeted drug also runs into many difficulties.The expense of targeted drug is very high, and its effectiveness is very huge because of the different difference of individual physique, so be everyone, does not want can gather in the crops satisfied effect after expensive medical expense having spent.Targeted drug in use also inevitably there will be drug resistance phenomenon in addition.
With respect to western medicine, Chinese medicine is indispensable equally in treatment of cancer.Chinese medicine can improve patient immune function and anti-cancer ability, yet contributes to patient to spend smoothly convalescence., there is slow, the inferior position such as uncertain therapeutic efficacy is cut that takes effect in simple treatment by Chinese herbs, seldom as the Main Means for the treatment of of cancer.
Therefore, one of main target of current cancer Comprehensive Treatment is found and a kind ofly can be significantly improved the therapeutic strategy that curative effect also effectively reduces existing drug dose simultaneously and reduces cancerous cell Drug tolerance.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of anticancer pharmaceutical composition that comprises targeted drug, chemotherapeutics and Chinese medicine is provided.Particularly, pharmaceutical composition of the present invention is to mix targeted drug, chemotherapeutics and Chinese medicine with specific ratio, and described targeting and chemotherapeutics administration are simultaneously preferred, the administration simultaneously of described targeting medicine, chemotherapeutic and Chinese medicine.
Described drug regimen has special synergistic therapeutic action to NSCLC.
In the present invention, " targeted drug " pointer is obvious to antineoplaston high specificity, the therapeutic effect of the specific molecular shot design of tumor, and normal tissue cell injury is less simultaneously, the compound that untoward reaction is lighter.In the present invention, preferred targeted drug is selected from one or more in bortezomib, imatinib, gefitinib and Sutent.Bortezomib is a kind of proteasome inhibitor of cell death inducing, can stop cancerous cell to decompose cell death related protein.Be mainly used in treating multiple myeloma.Imatinib is a kind of Abl-Ber tyrosine kinase inhibitor, is mainly used in treatment in chronic myelocytic leukemia.Gefitinib is a kind of EGFR inhibitor, is mainly used in treating advanced NSCLC.Sutent acts on platelet derived growth factor and vascular endothelial growth factor receptor, is mainly used in treating gastrointestinal stromal tumors and metastatic renal cell cancer.
" chemotherapeutics " refers to the chemicals with the growth of anticancer by blocking-up cell division.In the present invention, preferred chemotherapeutics is selected from one or more in 5-fluorouracil, fludarabine, carboplatin, amycin and epirubicin.5-fluorouracil and fludarabine belong to antimetabolitas.Carboplatin is a kind of DNA cross-linking agent.Amycin and epirubicin belong to topoenzyme inhibitor class medicine.
" Chinese medicine " refers to embody the Chinese herbal medicine of Chinese medicine anti-cancer and cancer-preventing tradition rule for the treatment of strengthening the body resistance, heat-clearing and toxic substances removing, promoting flow of QI and blood, softening the hard mass heavily fortified point.In the present invention, preferred Chinese medicine is selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Radix Salviae Miltiorrhizae, this product is the dry root and rhizome of labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bunge..Spring, Qiu Erji excavate, and remove silt, dry.Bitter in the mouth, is slightly cold; GUIXIN, Liver Channel.There is stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the function of the relieving restlessness that clears away heart-fire.
The Radix Astragali, this product is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Radix Astragali Astragalus membranaceus (Fisch.) Bge..Spring, Qiu Erji excavate, and remove fibrous root and root head, dry.Sweet in the mouth, temperature; Return lung, spleen channel.There is invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, the function of expelling pus and promoting granulation.
Lignum Sappan, this product is the dry duramen of pulse family Caesalpinia Lignum Sappan Caesalpinia sappan L..More than felling autumn, remove white sapwood, dry.Sweet-salty is flat, nontoxic; GUIXIN, liver, spleen channel.There is blood circulation promoting and blood stasis dispelling, the function of subduing swelling and relieving pain.
The Radix Pulsatillae, the dry root of the plant Radix Pulsatillae Pulsatilla chinensis of gelsemium section (Bge.) Regel.Spring, Qiu Erji excavate, and remove silt, dry.Bitter in the mouth, cold; Return stomach, large intestine channel.There is heat-clearing and toxic substances removing, the function of eliminating pathogenic heat from blood to cure dysentery.
Herba portulacae, this product is portulacaceous plant Herba Portulacae Portulaca oleracea L., with all herbal medicine.Sour in the mouth, cold; Enter large intestine, liver, spleen channel.There is clearing away heat-damp and promoting diuresis, the function of removing pathogenic heat from blood and toxic substance from the body.
In aforementioned pharmaceutical compositions, preferred, described targeted drug is bortezomib, and described chemotherapeutics is 5-fluorouracil.
As a kind of preferred embodiment, the targeted drug in pharmaceutical composition of the present invention is gefitinib, and chemotherapeutics is 5-fluorouracil.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is carboplatin.
Preferably, described targeted drug is imatinib, and described chemotherapeutics is 5-fluorouracil.
Preferably, described targeted drug is Sutent, and described chemotherapeutics is 5-fluorouracil.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is epirubicin.
Preferably, described targeted drug is Sutent, and described chemotherapeutics is amycin.
Preferably, described targeted drug is imatinib, and described chemotherapeutics is amycin.
Preferably, described targeted drug is gefitinib, and described chemotherapeutics is amycin.
Preferably, described targeted drug is Sutent, and described chemotherapeutics is epirubicin.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is fludarabine.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is 5-fluorouracil, and described Chinese medicine is to be selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is gefitinib, and described chemotherapeutics is 5-fluorouracil, and described Chinese medicine is a kind of for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is carboplatin, and described Chinese medicine is a kind of for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is imatinib, and described chemotherapeutics is 5-fluorouracil, and described Chinese medicine is for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae one or more.
Preferably, described targeted drug is Sutent, described chemotherapeutics 5-fluorouracil, and described Chinese medicine is for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae one or more.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is epirubicin, and described Chinese medicine is for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae one or more.
Preferably, described targeted drug is Sutent, and described chemotherapeutics is amycin, and described Chinese medicine is for being selected from Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae one or more.
Preferably, described targeted drug is imatinib, and described chemotherapeutics is amycin, and described Chinese medicine is to be selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is gefitinib, and described chemotherapeutics is amycin, and described Chinese medicine is to be selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is Sutent, and described chemotherapeutics is epirubicin, and described Chinese medicine is to be selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Preferably, described targeted drug is bortezomib, and described chemotherapeutics is fludarabine, and described Chinese medicine is to be selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
Pharmaceutical composition of the present invention is in the application for the preparation of in non-small cell lung cancer drug.
The present invention is the combined therapy effect to NSCLC by the different cancer therapy drug combinations of systematic research.Find that specific targeted drug, chemotherapeutics and Chinese medicine have synergistic function in various degree.Cell experiment proves that drug regimen of the present invention can effectively kill lung carcinoma cell, suppresses proliferation of lung cancer cells.This method can effectively reduce drug dose, reduces drug toxicity, overcomes single medicine resistance.
Accompanying drawing explanation
Fig. 1: the growth curve of A549 cell under different pharmaceutical independent role.(A) growth curve of A549 cell under bortezomib effect; (B) growth curve of A549 cell under gefitinib effect; (C) growth curve of A549 cell under imatinib effect; (D) growth curve of A549 cell under Sutent effect; (E) growth curve of A549 cell under 5-fluorouracil effect; (F) growth curve of A549 cell under fludarabine effect; (G) growth curve of A549 cell under epirubicin effect; (H) growth curve of A549 cell under amycin effect; (I) growth curve of A549 cell under carboplatin effect.
Fig. 2: the Fa-CI curve of A549 cell under different pharmaceutical compound action.(A) the Fa-CI curve of A549 cell under the compound action of bortezomib and 5-fluorouracil; (B) the Fa-CI curve of A549 cell under the compound action of gefitinib and 5-fluorouracil; (C) the Fa-CI curve of A549 cell under the compound action of bortezomib and carboplatin; (D) the Fa-CI curve of A549 cell under the compound action of imatinib and 5-fluorouracil; (E) the Fa-CI curve of A549 cell under the compound action of Sutent and 5-fluorouracil; (F) the Fa-CI curve of A549 cell under the compound action of bortezomib and epirubicin; (G) the Fa-CI curve of A549 cell under the compound action of Sutent and amycin; (H) the Fa-CI curve of A549 cell under the compound action of imatinib and amycin; (I) the Fa-CI curve of A549 cell under the compound action of gefitinib and amycin; (J) the Fa-CI curve of A549 cell under the compound action of Sutent and epirubicin; (K) the Fa-CI curve of A549 cell under the compound action of bortezomib and fludarabine;
The specific embodiment
Below in conjunction with chart and embodiment, the present invention will be further described.
Embodiment 1: the effect of the combination of having assessed different targeted drugs and chemotherapeutics to NSCLC cell line.
Cell culture: the NSCLC cell of testing in experiment is the A549 cell available from ATCC.Cell culture medium used is for being supplemented with the RPMI medium1640 culture fluid of 10% hyclone (FBS), 100U/mL penicillin and 100 μ g/mL streptomycins, the CO that is 5% at 37 ℃, volume fraction
2in incubator, cultivate, cell is adherent growth, the trophophase cell of all taking the logarithm during experiment.
Screening minute two parts carry out:
A. in first group of experiment, measure and to be exposed in NSCLC cell line the half-inhibition concentration (IC of each medicine after 72 hours
50) value.Concrete steps are as follows:
Collect logarithmic (log) phase cell, be inoculated in 96 orifice plates, every hole adds 100 μ L, adjusts concentration of cell suspension and makes every hole contain 2000-4000 cell.Cultivate after 24 hours, cell is exposed in the medicine of variable concentrations.Drug level keeps 7-8 Concentraton gradient, and establishes blank group and positive controls, and every concentration is established 5 multiple holes.Cultivate after 72 hours, every hole adds 20 μ L MTT solution (5mg/ml, i.e. 0.5%MTT), continues to cultivate 4h, and centrifugal 96 orifice plates of 2000r/min, utilize siphon principle to discard culture fluid.Every hole adds 150 μ L dimethyl sulfoxide, puts the 10min that vibrates on shaking table.At microplate reader 490nm wavelength place, measure the light absorption value (OD value) in each hole.By following formula, calculate inhibitory rate of cell growth: growth inhibition ratio=(1-experimental group absorbance/matched group absorbance) * 100%.Experiment in triplicate.Draw dose effect curve (Fig. 1) and calculate the IC of every kind of medicine
50be worth as shown in table 1.
Table 1: single medicine act on NSCLC cell line IC
50value
B. in second group of experiment, measured the inhibitory action of above-mentioned various cancer therapy drug combination to NSCLC cell line.Experiment Chinese medicine is with the combination of fixed dosage ratio, and this fixed dosage ratio is corresponding to the single IC50 value of independent every kind of medicine.Drug level keeps 78 Concentraton gradient.Finally with Chou-Talalay Equation for Calculating association index (CI), evaluate the potentiation of drug regimen:
In formula, (D
x)
1(D
x)
2while representing two kinds of medicine individualisms, suppression ratio reaches the concentration of x%.(D)
1(D)
2represent that suppression ratio when two kinds of medicines exist simultaneously reaches the concentration of x%.CI<1 ,=1 and >1 represents respectively to work in coordination with, cumulative sum antagonism (Chou TC and Talalay P.Adv.Enzyme Regul.1984,22,27-55).CompuSyn software (ComboSyn, Inc, Paramus, NJ) is analyzed (Fig. 2) for CI association index.Due in cytotoxicity experiment, combined effect during high suppression ratio is more important with respect to low suppression ratio, so the CI that we have defined a weighting carrys out quantized combinations effect: CI
wt=[CI
50+ 2CI
75+ 3CI
90+ 4CI
95]/10, subscript represents different suppression ratio.Table 2 provide that various dose compound action obtains when A549 cell line association index (CI).
Table 2: the CI value that drug regimen obtains while acting on A549 cell line
Experimental result shows:
The combination of bortezomib and 5-fluorouracil has extremely strong synergism (CI<0.1).
Gefitinib and 5-fluorouracil, bortezomib and carboplatin, three combinations of imatinib and 5-fluorouracil have strong synergism (0.1<CI<0.3).
Sutent and 5-fluorouracil, bortezomib and epirubicin, Sutent and amycin, imatinib and amycin, gefitinib and amycin, six combinations of Sutent and epirubicin have synergism (0.3<CI<0.7).
The combination of bortezomib and fludarabine has weak synergism (0.85<CI<0.9).
Embodiment 2: assessed the impact of Radix Salviae Miltiorrhizae on targeting medicine and chemotherapeutic combination antitumaous effect.
The preparation of Salvia miltiorrhiza Bge water extract: 80g Radix Salviae Miltiorrhizae decocts medicinal liquid for 3 times and filters through vacuum filter, concentrated into about 40ml medicinal liquid, put into vacuum drying oven dry, by 100% concentration, calculate yield.Get lg water extract, add 10ml ultra-pure water, dissolving, centrifugal, gets supernatant, then through 0.22 μ m microporous filter membrane degerming, makes mother liquid concentration 100mg/ml, puts-20 ℃ of refrigerators standby.
Cell experiment step and method is all identical with embodiment 1, and difference is to have increased by one group of dosing group, and wherein the amount of targeting and chemotherapeutics combination is constant, but has increased the Salvia miltiorrhiza Bge water extract of 10mg/ml.Result is as shown in table 3, and after adding Salvia miltiorrhiza Bge water extract, targeting and chemotherapeutics compound action are in the IC of A549 cell
50value all has decline to a certain degree, show radix Salviae Miltiorrhizae water extract can intensifier target to the antitumaous effect with chemotherapeutics combination.
Embodiment 3: assessed the impact of the Radix Astragali on targeting medicine and chemotherapeutic combination antitumaous effect.
The preparation of water extraction of astragalus membranaceus: the 80g Radix Astragali decocts medicinal liquid for 3 times and filters through vacuum filter, concentrated into about 40ml medicinal liquid, put into vacuum drying oven dry, by 100% concentration, calculate yield.Get lg water extract, add 10ml ultra-pure water, dissolving, centrifugal, gets supernatant, then through 0.22 μ m microporous filter membrane degerming, makes mother liquid concentration 100mg/ml, puts-20 ℃ of refrigerators standby.
Cell experiment step and method is all identical with embodiment 1, and difference is to have increased by one group of dosing group, and wherein the amount of targeting and chemotherapeutics combination is constant, but has increased the water extraction of astragalus membranaceus of 10mg/ml.Result is as shown in table 3, and after adding water extraction of astragalus membranaceus, targeting and chemotherapeutics compound action are in the IC of A549 cell
50value all has decline to a certain degree, show Radix Astragali water extract can intensifier target to the antitumaous effect with chemotherapeutics combination.
Embodiment 4: assessed the impact of Lignum Sappan on targeting medicine and chemotherapeutic combination antitumaous effect.
The preparation of Lignum Sappan water extraction liquid: 80g Lignum Sappan decocts medicinal liquid for 3 times and filters through vacuum filter, concentrated into about 40ml medicinal liquid, put into vacuum drying oven dry, by 100% concentration, calculate yield.Get lg water extract, add 10ml ultra-pure water, dissolving, centrifugal, gets supernatant, then through 0.22 μ m microporous filter membrane degerming, makes mother liquid concentration 100mg/ml, puts-20 ℃ of refrigerators standby.
Cell experiment step and method is all identical with embodiment 1, and difference is to have increased by one group of dosing group, and wherein the amount of targeting and chemotherapeutics combination is constant, but has increased the Lignum Sappan water extraction liquid of 10mg/ml.Result is as shown in table 3, and after adding Lignum Sappan water extraction liquid, targeting and chemotherapeutics compound action are in the IC of A549 cell
50value all has decline to a certain degree, show aqueous extract of lignum sappan can intensifier target to the antitumaous effect with chemotherapeutics combination.
Embodiment 5: assessed the impact of the Radix Pulsatillae on targeting medicine and chemotherapeutic combination antitumaous effect.
The preparation of Radix Pulsatillae water extraction liquid: the 80g Radix Pulsatillae decocts medicinal liquid for 3 times and filters through vacuum filter, concentrated into about 40ml medicinal liquid, put into vacuum drying oven dry, by 100% concentration, calculate yield.Get lg water extract, add 10ml ultra-pure water, dissolving, centrifugal, gets supernatant, then through 0.22 μ m microporous filter membrane degerming, makes mother liquid concentration 100mg/ml, puts-20 ℃ of refrigerators standby.
Cell experiment step and method is all identical with embodiment 1, and difference is to have increased by one group of dosing group, and wherein the amount of targeting and chemotherapeutics combination is constant, but has increased the Radix Pulsatillae water extraction liquid of 10mg/ml.Result is as shown in table 3, and after adding Radix Pulsatillae water extraction liquid, targeting and chemotherapeutics compound action are in the IC of A549 cell
50value all has decline to a certain degree, show Radix Pulsatillae water extract can intensifier target to the antitumaous effect with chemotherapeutics combination.
Embodiment 6: assessed the impact of Herba portulacae on targeting medicine and chemotherapeutic combination antitumaous effect.
The preparation of Herba portulacae water extraction liquid: 80g Herba portulacae decocts medicinal liquid for 3 times and filters through vacuum filter, concentrated into about 40ml medicinal liquid, put into vacuum drying oven dry, by 100% concentration, calculate yield.Get lg water extract, add 10ml ultra-pure water, dissolving, centrifugal, gets supernatant, then through 0.22 μ m microporous filter membrane degerming, makes mother liquid concentration 100mg/ml, puts-20 ℃ of refrigerators standby.
Cell experiment step and method is all identical with embodiment 1, and difference is to have increased by one group of administration group, and wherein the amount of targeting and chemotherapeutics combination is constant, but has increased the Herba portulacae water extraction liquid of 10mg/ml.Result is as shown in table 3, and after adding Herba portulacae water extraction liquid, targeting and chemotherapeutics compound action are in the IC of A549 cell
50value all has decline to a certain degree, show Herba portulacae water extract can intensifier target to the antitumaous effect with chemotherapeutics combination.
Table 3: different Chinese medicine on targeting and chemotherapeutics compound action in the impact of NSCLC cell line
Above specific embodiments of the invention be have been described in detail, but it is just as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and alternative also all among category of the present invention.Therefore, equalization conversion and the modification done without departing from the spirit and scope of the invention, all should contain within the scope of the invention.
Claims (5)
1. the pharmaceutical composition that is used for the treatment of nonsmall-cell lung cancer, is characterized in that, described pharmaceutical composition comprises targeted drug, chemotherapeutics and Chinese medicine; Wherein, the administration simultaneously of described targeting and chemotherapeutics, the administration simultaneously of described targeting medicine, chemotherapeutic and Chinese medicine.
2. the pharmaceutical composition that is used for the treatment of nonsmall-cell lung cancer according to claim 1, wherein said targeted drug is selected from one or more in bortezomib, imatinib, gefitinib and Sutent.
3. the pharmaceutical composition that is used for the treatment of nonsmall-cell lung cancer according to claim 1, wherein said chemotherapeutics is selected from one or more in 5-fluorouracil, carboplatin, epirubicin, amycin and fludarabine.
4. the pharmaceutical composition that is used for the treatment of nonsmall-cell lung cancer according to claim 1, wherein said Chinese medicine is selected from one or more in Radix Salviae Miltiorrhizae, the Radix Astragali, Lignum Sappan, the Radix Pulsatillae and Herba portulacae.
In claim 1-4 the pharmaceutical composition of any one in the application for the preparation of in non-small cell lung cancer drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151272.1A CN103948689A (en) | 2014-04-15 | 2014-04-15 | Medicinal composition for treating non-small cell lung cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410151272.1A CN103948689A (en) | 2014-04-15 | 2014-04-15 | Medicinal composition for treating non-small cell lung cancer and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103948689A true CN103948689A (en) | 2014-07-30 |
Family
ID=51326131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410151272.1A Pending CN103948689A (en) | 2014-04-15 | 2014-04-15 | Medicinal composition for treating non-small cell lung cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948689A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267793A (en) * | 2015-11-26 | 2016-01-27 | 紫光古汉集团股份有限公司 | New application of traditional Chinese medicine composition |
| CN105748467A (en) * | 2016-02-03 | 2016-07-13 | 吴卫兵 | Pharmaceutical composition with effect of resisting lung cancer |
| WO2016150340A1 (en) * | 2015-03-20 | 2016-09-29 | 正大天晴药业集团股份有限公司 | Salts of quinazoline derivative and method for preparing same |
| WO2016197012A1 (en) * | 2015-06-03 | 2016-12-08 | Orient Pharma Inc. | Methods and compositions for treating non-small cell lung cancer |
| CN107684563A (en) * | 2016-12-07 | 2018-02-13 | 四川好医生攀西药业有限责任公司 | A kind of medicine containing American cockroach and Imatinib and its application |
| CN107693545A (en) * | 2016-12-07 | 2018-02-16 | 四川好医生攀西药业有限责任公司 | A kind of combination medicine for treating non-small cell lung cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125140A (en) * | 2007-09-18 | 2008-02-20 | 浙江大学 | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect |
| WO2011116351A2 (en) * | 2010-03-19 | 2011-09-22 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| CN102247340A (en) * | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | Application of apogossypol ketone in preparation of drugs for treating tumor diseases |
-
2014
- 2014-04-15 CN CN201410151272.1A patent/CN103948689A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125140A (en) * | 2007-09-18 | 2008-02-20 | 浙江大学 | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect |
| WO2011116351A2 (en) * | 2010-03-19 | 2011-09-22 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| CN102247340A (en) * | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | Application of apogossypol ketone in preparation of drugs for treating tumor diseases |
Non-Patent Citations (3)
| Title |
|---|
| 周秋丽等: "《现代中药基础研究与临床》", 30 June 2012, 天津科技翻译出版公司 * |
| 魏长志等: "《抗肿瘤中药集锦》", 31 August 2010, article "丹参", pages: 231 * |
| 魏长志等: "《抗肿瘤中药集锦》", 31 August 2010, 中医古籍出版社 * |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107406430A (en) * | 2015-03-20 | 2017-11-28 | 正大天晴药业集团股份有限公司 | Salt of quinazoline derivant and preparation method thereof |
| RU2720810C2 (en) * | 2015-03-20 | 2020-05-13 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Salts of a quinazoline derivative and a method for production thereof |
| WO2016150340A1 (en) * | 2015-03-20 | 2016-09-29 | 正大天晴药业集团股份有限公司 | Salts of quinazoline derivative and method for preparing same |
| CN107406430B (en) * | 2015-03-20 | 2019-04-26 | 正大天晴药业集团股份有限公司 | Salt of quinazoline derivant and preparation method thereof |
| US10231973B2 (en) | 2015-03-20 | 2019-03-19 | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. | Salts of quinazoline derivative and method for preparing the same |
| KR20180027440A (en) * | 2015-06-03 | 2018-03-14 | 오피 나노 컴퍼니, 리미티드 | Therapeutic methods for the treatment of non-small cell lung cancer and compositions therefor |
| CN108289922A (en) * | 2015-06-03 | 2018-07-17 | 友杏生技医药股份有限公司 | Treatment and composition for for treating non-small cell lung cancer |
| KR101941399B1 (en) | 2015-06-03 | 2019-04-17 | 오피 나노 컴퍼니, 리미티드 | eng |
| WO2016197012A1 (en) * | 2015-06-03 | 2016-12-08 | Orient Pharma Inc. | Methods and compositions for treating non-small cell lung cancer |
| US10953059B2 (en) | 2015-06-03 | 2021-03-23 | Chang Gung Medical Foundation Keelung Chang Gung Memorial Hospital | Methods and compositions for treating non-small cell lung cancer |
| CN108289922B (en) * | 2015-06-03 | 2022-02-08 | 友杏生技医药股份有限公司 | Therapeutic methods and compositions for treating non-small cell lung cancer |
| CN105267793A (en) * | 2015-11-26 | 2016-01-27 | 紫光古汉集团股份有限公司 | New application of traditional Chinese medicine composition |
| CN105748467B (en) * | 2016-02-03 | 2017-02-01 | 吴卫兵 | Pharmaceutical composition with effect of resisting lung cancer |
| CN105748467A (en) * | 2016-02-03 | 2016-07-13 | 吴卫兵 | Pharmaceutical composition with effect of resisting lung cancer |
| CN107684563A (en) * | 2016-12-07 | 2018-02-13 | 四川好医生攀西药业有限责任公司 | A kind of medicine containing American cockroach and Imatinib and its application |
| CN107693545A (en) * | 2016-12-07 | 2018-02-16 | 四川好医生攀西药业有限责任公司 | A kind of combination medicine for treating non-small cell lung cancer |
| CN107693545B (en) * | 2016-12-07 | 2020-08-25 | 四川好医生攀西药业有限责任公司 | Combined medicine for treating non-small cell lung cancer |
| CN107684563B (en) * | 2016-12-07 | 2020-08-25 | 四川好医生攀西药业有限责任公司 | Medicine containing periplaneta americana and imatinib and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948689A (en) | Medicinal composition for treating non-small cell lung cancer and application thereof | |
| CN1706473A (en) | Anticancer taxad Chinese medicine prepn | |
| CN101342271B (en) | Traditional Chinese medicine for treating qi-blood deficiency caused by tumour chemotherapy and preparation method thereof | |
| CN104491740A (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN101590209B (en) | Medicament for treating tumors and preparation method thereof | |
| CN109010495B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103933541B (en) | A kind of glutathion anti-cancer composition | |
| CN103385830A (en) | Traditional Chinese medicine composition and its preparation method and use | |
| CN1733000A (en) | Ceratopteris richardii extract and its application in preparation of anti-tumor formulation | |
| CN102961440A (en) | Pharmaceutical composition containing cyclooxygenase and natural doxorubicin or doxorubicin-like substances, its preparation method and application in preparation of multiple drugs | |
| CN102091312A (en) | Ginger and wild pepper composition and preparation method thereof, and application of ginger and wild pepper composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN101745052B (en) | Medicament for treating tumors and preparation method thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN105477432A (en) | Medicine composition for treating tumors | |
| CN101007047B (en) | An antitumor medicine composition and its preparation method | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN103735689B (en) | A kind of natural drug composition is preparing the application in anoxia enduring medicine and health product | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN103230496A (en) | Traditional Chinese medicine extract and preparation method thereof | |
| CN102552541B (en) | Medicinal composition for preventing or treating breast cancer | |
| CN102139037A (en) | Application of rhizoma paridis total saponins in preparation of adjuvant drugs of anti-cancer drugs | |
| CN103495002B (en) | A kind of antineoplastic Chinese medicine composition and its preparation method and application | |
| CN104069192B (en) | A traditional Chinese medicine composition having anticancer effects and a preparing method and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140730 |